Posted by Michael Wonder on 26 Jun 2017
Shire announces EMA validation of Veyvondi [von Willebrand factor (recombinant)] marketing authorisation application for treatment of von Willebrand disease
22 June 2017 - Veyvondi is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding disorder.
Shire today announced that the EMA validated the marketing authorisation application for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults (age 18 and older) diagnosed with von Willebrand Disease (VWD), the most common inherited bleeding disorder.
Currently available in the U.S. as Vonvendi [von Willebrand factor (Recombinant)], Veyvondi is the first and only recombinant von Willebrand factor (rVWF) treatment for adults living with VWD.
